Who are Standard therapy for INCS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin only, Metformin / Pioglitazone Pill, MET, Metformin IR, Metformin and Pioglitazone, Metformin plus clomiphene citrate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-therapy-for-incs.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Standard therapy for INCS — Competitive Intelligence Brief

Standard therapy for INCS (Standard therapy for INCS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: biguanide. Area: Diabetes.

phase 3 biguanide Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Standard therapy for INCS (Standard therapy for INCS) — Eli Lilly and Company. Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Standard therapy for INCS TARGET	Standard therapy for INCS	Eli Lilly and Company	phase 3	biguanide
Metformin only	Metformin only	Sheba Medical Center	marketed	Biguanide	AMP-activated protein kinase (AMPK), mitochondrial complex I
Metformin / Pioglitazone Pill	Metformin / Pioglitazone Pill	University of Catanzaro	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK activation (metformin); PPAR-γ (pioglitazone)
MET	MET	Ente Ospedaliero Ospedali Galliera	marketed	Biguanide	AMP-activated protein kinase (AMPK) / mitochondrial complex I
Metformin IR	Metformin IR	AstraZeneca	marketed	Biguanide	AMP-activated protein kinase (AMPK)
Metformin and Pioglitazone	Metformin and Pioglitazone	King Edward Medical University	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	Metformin: AMP-activated protein kinase (AMPK) pathway; Pioglitazone: PPAR-gamma
Metformin plus clomiphene citrate	Metformin plus clomiphene citrate	University Magna Graecia	marketed	Combination therapy: biguanide + selective estrogen receptor modulator (SERM)	Insulin signaling pathway (metformin); estrogen receptor (clomiphene citrate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (biguanide class)

Eli Lilly and Company · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard therapy for INCS — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-therapy-for-incs. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab